Presentation is loading. Please wait.

Presentation is loading. Please wait.

by Peter Bacchetti, Steven G. Deeks, and Joseph M. McCune

Published by忘城 胡 Modified over 5 years ago

Similar presentations

Presentation on theme: "by Peter Bacchetti, Steven G. Deeks, and Joseph M. McCune"— Presentation transcript:

1 by Peter Bacchetti, Steven G. Deeks, and Joseph M. McCune
Breaking Free of Sample Size Dogma to Perform Innovative Translational Research by Peter Bacchetti, Steven G. Deeks, and Joseph M. McCune Sci Transl Med Volume 3(87):87ps24-87ps24 June 15, 2011 Copyright © 2011, American Association for the Advancement of Science

2 Fig. 1. How sample size influences the scientific or practical value that a study can be expected to produce, under three different scenarios. How sample size influences the scientific or practical value that a study can be expected to produce, under three different scenarios. Numeric labels on the axes are absent because specific values will differ for different studies, but the qualitative relationship illustrated applies to all studies of new ideas. When the idea is a fundamental breakthrough, this will usually be apparent from a relatively small study. A much larger sample size does not produce much additional value. Similarly, when the idea is completely off-target, this will usually be apparent from a relatively small study. In intermediate cases, larger sample sizes might add value. However, increasing sample size still produces diminishing marginal returns. Peter Bacchetti et al., Sci Transl Med 2011;3:87ps24 Copyright © 2011, American Association for the Advancement of Science

Download ppt "by Peter Bacchetti, Steven G. Deeks, and Joseph M. McCune"

Similar presentations

Deep Sequencing of Patient Genomes for Disease Diagnosis: When Will It Become Routine? by Stephen F. Kingsmore, and Carol J. Saunders Sci Transl Med Volume.

Deep Sequencing of Patient Genomes for Disease Diagnosis: When Will It Become Routine? by Stephen F. Kingsmore, and Carol J. Saunders Sci Transl Med Volume.
The Bayh-Dole Act Turns 30 by Vicki Loise, and Ashley J. Stevens Sci Transl Med Volume 2(52):52cm27-52cm27 October 6, 2010 Published by AAAS.

The Bayh-Dole Act Turns 30 by Vicki Loise, and Ashley J. Stevens Sci Transl Med Volume 2(52):52cm27-52cm27 October 6, 2010 Published by AAAS.
Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.
Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.
Fig. 7 Correlation of NHP and human ISGs.

Fig. 7 Correlation of NHP and human ISGs.
Fig. 1 Movement percepts for all participants.

Fig. 1 Movement percepts for all participants.
Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.

Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.
Consolidated Standards of Reporting Trials flow diagram of VRC trial

Consolidated Standards of Reporting Trials flow diagram of VRC trial
Fig. 4 Labeling of Msmeg with DMN-Tre is fast and specific and depends on Ag85A function. Labeling of Msmeg with DMN-Tre is fast and specific and depends.

Fig. 4 Labeling of Msmeg with DMN-Tre is fast and specific and depends on Ag85A function. Labeling of Msmeg with DMN-Tre is fast and specific and depends.
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Filipin staining of marginal gyrus of cerebral cortex in NPC cats

Filipin staining of marginal gyrus of cerebral cortex in NPC cats
Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.
Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.

Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.
Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.
Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.
Fig. 3 Projected gains in MCP.

Fig. 3 Projected gains in MCP.
Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.
In vivo release of doxycycline hyclate from the GRS in a swine model

In vivo release of doxycycline hyclate from the GRS in a swine model
Fig. 4 Deorphanization of quinine and mefloquine protein targets.

Fig. 4 Deorphanization of quinine and mefloquine protein targets.

Similar presentations

Ads by Google